腹膜透析相关嗜酸粒细胞性腹膜炎一例

One Case of Peritoneal Dialysis-Associated Eosinophilic Peritonitis

摘要: 腹膜透析(PD)是终末期肾病的肾脏替代治疗方式之一，相对于血液透析(HD)，PD具有操作简单、成本较低、可居家治疗的独特优势，尽管近年来透析装置的不断进步，医务人员无菌操作观念逐渐加强，但是PD患者在并发症上面仍面临着挑战。其中，腹膜透析相关性腹膜炎(PDAD)被认为是腹膜透析常见的并发症，而嗜酸性粒细胞性腹膜炎(EP)是一种罕见的非感染性腹膜透析相关性腹膜炎，随着PD使用的增加，EP患者总数可能仍会上升。近年来，随着PD技术的发展及实施，EP的病例报道有所增加，但国内鲜有报道。我院于2021年5月收治1例腹膜透析相关嗜酸粒粒细胞性腹膜炎，经激素治疗后症状缓解，现将诊治情况报道如下。

Abstract: Peritoneal dialysis (PD) is one of the renal replacement therapies for end-stage renal disease. Compared with hemodialysis (HD), PD has the unique advantages of simple operation, low cost and home treatment. Despite the continuous progress of dialysis devices in recent years and the gradual strengthening of the concept of aseptic operation of medical staff, PD patients still face challenges in complications. Among them, peritoneal dialysis-associated peritonitis (PDAD) is considered to be a common complication of peritoneal dialysis and is associated with a large number of morbidity and mortality. Eosinophil granulocyte peritonitis (EP) is a rare non-infectious peritoneal dialysis associated peritonitis. With the increasing use of PD, the total number of EP patients may still increase. In recent years, with the development and application of PD technique in medulla, the reports of EP cases have increased, but there are few reports in China. A case of peritoneal dialysis-associated eosinophilic peritonitis was 2021 in our hospital in May. The symptoms were relieved after hormone treatment. The diagnosis and treatment situation is now reported as follows.